Freenome, Inc.

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen™ CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation among millions of at-risk individuals. For more information, visit www.freenome.com.

Current securities

1. S-8 filingSep 23, 2026
2. 424B3 filingAug 27, 2026
3. S-1 filingAug 18, 2026
4. SCHEDULE 13G/A filingAug 14, 2026
5. Completion of Acquisition or Disposition of AssetsAug 13, 2026